Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class ...

A study shows that patients with obesity and fatty liver-related cirrhosis who had bariatric (weight-loss) surgery significantly lowered their future risk of ... Obesity and diabetes are the ...

Doctors say new research has found a link between weight-loss drugs and cancer, putting users at 'significantly higher risk' of the disease. The injections were originally made to tackle diabetes ...

Popular weight loss injections including Ozempic, Wegovy and Mounjaro could increase the risk of thyroid cancer within the ...

Sarah is an experienced writer and editor enthusiastic about helping readers live their healthiest and happiest lives. Before joining Forbes Health, Sarah worked as a writer for various digital ...

Prevoius research has found that Ozempic, Wegovy and Mounjaro users are 50% more at risk of developing pancreatitis compared to people not using weight loss jabs. People with pancreatitis can feel ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

Olatec Therapeutics, Inc., a leader in the developing class of selective NLRP3 inhibitors, today announced that long-time ...

Your weight tells only part of the story. Body composition reveals the real truth about health, fitness, and longevity beyond the scale.

You’ve long heard doctors talk about BMI — or body mass index — and you may even know yours off the top of your head, especially if you were told your number was in the unhealthy range.

Belly fat could be a sign that your health is at risk, with Type-2 diabetes ... your weight and belly fat quite quickly. * If you are underweight, you should not follow a weight-loss plan.